Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $7.49, but opened at $7.24. Recursion Pharmaceuticals shares last traded at $7.18, with a volume of 3,042,116 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RXRX shares. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.75.

Recursion Pharmaceuticals Stock Up 1.5 %

The firm has a market capitalization of $2.97 billion, a PE ratio of -4.97 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $6.86 and a 200-day moving average price of $6.94.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.43) earnings per share. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the sale, the director now owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,894 shares of company stock worth $279,279 over the last ninety days. Company insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter worth about $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $26,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after buying an additional 3,377 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.